132 related articles for article (PubMed ID: 36512100)
1. Role of senescent tumor cells in building a cytokine shield in the tumor microenvironment: mathematical modeling.
Kim Y; Lee J; Lee C; Lawler S
J Math Biol; 2022 Dec; 86(1):14. PubMed ID: 36512100
[TBL] [Abstract][Full Text] [Related]
2. Senescent Tumor Cells Build a Cytokine Shield in Colorectal Cancer.
Choi YW; Kim YH; Oh SY; Suh KW; Kim YS; Lee GY; Yoon JE; Park SS; Lee YK; Park YJ; Kim HS; Park SH; Kim JH; Park TJ
Adv Sci (Weinh); 2021 Feb; 8(4):2002497. PubMed ID: 33643790
[TBL] [Abstract][Full Text] [Related]
3. Senescent tumor cells: an overlooked adversary in the battle against cancer.
Park SS; Choi YW; Kim JH; Kim HS; Park TJ
Exp Mol Med; 2021 Dec; 53(12):1834-1841. PubMed ID: 34916607
[TBL] [Abstract][Full Text] [Related]
4. CXCL12 Signaling in the Tumor Microenvironment.
Portella L; Bello AM; Scala S
Adv Exp Med Biol; 2021; 1302():51-70. PubMed ID: 34286441
[TBL] [Abstract][Full Text] [Related]
5. T-helper 2 cytokines attenuate senescent eosinophil activation by the CXCR4 ligand stromal-derived factor-1alpha (CXCL12).
Dulkys Y; Buschermöhle T; Escher SE; Kapp A; Elsner J
Clin Exp Allergy; 2004 Oct; 34(10):1610-20. PubMed ID: 15479278
[TBL] [Abstract][Full Text] [Related]
6. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
7. Measurement of cellular chemotaxis with ECIS/Taxis.
Pietrosimone KM; Yin X; Knecht DA; Lynes MA
J Vis Exp; 2012 Apr; (62):. PubMed ID: 22491349
[TBL] [Abstract][Full Text] [Related]
8. Tumor microenvironment in functional adrenocortical adenomas: immune cell infiltration in cortisol-producing adrenocortical adenoma.
Kitawaki Y; Nakamura Y; Kubota-Nakayama F; Yamazaki Y; Miki Y; Hata S; Ise K; Kikuchi K; Morimoto R; Satoh F; Sasano H
Hum Pathol; 2018 Jul; 77():88-97. PubMed ID: 29596893
[TBL] [Abstract][Full Text] [Related]
9. Chemokine Heterocomplexes and Cancer: A Novel Chapter to Be Written in Tumor Immunity.
D'Agostino G; Cecchinato V; Uguccioni M
Front Immunol; 2018; 9():2185. PubMed ID: 30319638
[TBL] [Abstract][Full Text] [Related]
10. Cellular senescence and the tumour microenvironment.
Takasugi M; Yoshida Y; Ohtani N
Mol Oncol; 2022 Sep; 16(18):3333-3351. PubMed ID: 35674109
[TBL] [Abstract][Full Text] [Related]
11. The Role of the Tumor Microenvironment in Glioblastoma: A Mathematical Model.
Kim Y; Jeon H; Othmer H
IEEE Trans Biomed Eng; 2017 Mar; 64(3):519-527. PubMed ID: 27959794
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment.
Santagata S; Ieranò C; Trotta AM; Capiluongo A; Auletta F; Guardascione G; Scala S
Front Oncol; 2021; 11():591386. PubMed ID: 33937018
[TBL] [Abstract][Full Text] [Related]
13. Ketogenesis Attenuates KLF5-Dependent Production of CXCL12 to Overcome the Immunosuppressive Tumor Microenvironment in Colorectal Cancer.
Wei R; Zhou Y; Li C; Rychahou P; Zhang S; Titlow WB; Bauman G; Wu Y; Liu J; Wang C; Weiss HL; Evers BM; Wang Q
Cancer Res; 2022 Apr; 82(8):1575-1588. PubMed ID: 35247887
[TBL] [Abstract][Full Text] [Related]
14. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
[TBL] [Abstract][Full Text] [Related]
15. [Effect of chemokine CXCL12 and its receptor CXCR4 on proliferation, migration and invasion of epithelial ovarian cancer cells].
Jiang YP; Wu XH; Xing HY; DU XY
Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):403-7. PubMed ID: 17697603
[TBL] [Abstract][Full Text] [Related]
16. Senescent fibroblasts in melanoma initiation and progression: an integrated theoretical, experimental, and clinical approach.
Kim E; Rebecca V; Fedorenko IV; Messina JL; Mathew R; Maria-Engler SS; Basanta D; Smalley KS; Anderson AR
Cancer Res; 2013 Dec; 73(23):6874-85. PubMed ID: 24080279
[TBL] [Abstract][Full Text] [Related]
17. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
18. Senescence-Associated Molecules and Tumor-Immune-Interactions as Prognostic Biomarkers in Colorectal Cancer.
Kellers F; Fernandez A; Konukiewitz B; Schindeldecker M; Tagscherer KE; Heintz A; Jesinghaus M; Roth W; Foersch S
Front Med (Lausanne); 2022; 9():865230. PubMed ID: 35492321
[TBL] [Abstract][Full Text] [Related]
19. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
D'Alterio C; Buoncervello M; Ieranò C; Napolitano M; Portella L; Rea G; Barbieri A; Luciano A; Scognamiglio G; Tatangelo F; Anniciello AM; Monaco M; Cavalcanti E; Maiolino P; Romagnoli G; Arra C; Botti G; Gabriele L; Scala S
J Exp Clin Cancer Res; 2019 Oct; 38(1):432. PubMed ID: 31661001
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor promotes breast cancer cell chemotaxis in CXCL12 gradients.
Mosadegh B; Saadi W; Wang SJ; Jeon NL
Biotechnol Bioeng; 2008 Aug; 100(6):1205-13. PubMed ID: 18553401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
